The promise of ESCAT: a new system for evaluating cancer drug–target pairs

The promise of ESCAT: a new system for evaluating cancer drug–target pairsThe promise of ESCAT: a new system for evaluating cancer drug–target pairs, Published online: 13 October 2018; doi:10.1038/s41571-018-0110-3The ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) will be useful as a common language to harmonize discussions in precision oncology and could also guide policy and reimbursement decisions, but it is far from perfect. Herein, we highlight how ESCAT can be further improved to increase its utility in clinical and policy decisions.
Source: Nature Clinical Practice Oncology - Category: Cancer & Oncology Authors: Source Type: research